glp-1 receptor agonist antipsychotic weight gain study Semaglutide for the treatment of antipsychotic-associated in patients not responding to metformin – a case series Worth the Weight? The Challenges

Approval was granted on the basis that it had been shown to achieve a weight loss of over 25 percent or more in over a third of the participants in clinical trials

Nausea, diarrhea, and digestive discomfort occur somewhat more frequently with tirzepatide than with semaglutide

10.1016/S0140-6736(17)30069-7

Key findings include: Up to 14.7% reduction in mean body weight from baseline after 13 weekly doses

And new options for people averse to needles are coming

17 Patients should discuss with their providers strategies to improve glucose control such as taking insulin more often, changing the type of insulin they use, taking insulin after meals instead of before, or checking blood glucose levels more frequently after eating to determine when insulin admin-istration is necessary